Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs ALPHADERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Hypertension,Benign prostatic hyperplasia
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Hepatic via cytochrome P450 (CYP3A4); active metabolites.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
Approximately 85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Oral bioavailability is 70-80% due to first-pass metabolism; IM bioavailability is 90-95%.
No dose adjustment required. Topical use with minimal systemic absorption.
No dose adjustment required for renal impairment.
No dose adjustment required. Topical use with minimal systemic absorption.
No dose adjustment required for hepatic impairment.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Safety and efficacy in pediatric patients have not been established.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
No specific dose adjustment; use with caution due to potential increased skin fragility.
No FDA black box warning.
None.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Orthostatic hypotension and syncope, especially with first dose,May cause dizziness, drowsiness, or lightheadedness,Use caution in patients with hepatic impairment,May exacerbate angina or heart failure
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to alpha-blockers,History of orthostatic hypotension,Micturition syncope,Severe renal impairment,Concomitant use with PDE-5 inhibitors (e.g., sildenafil) due to risk of hypotension
No known food interactions with topical Aclovate.
No specific food interactions. However, high-fat meals may increase systemic absorption of topical tretinoin marginally; no dietary restrictions necessary. Avoid excessive vitamin A supplements to reduce risk of hypervitaminosis A.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fetal harm; avoid unless benefit outweighs risk.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
Unknown if excreted in human milk; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
Increased plasma volume may reduce drug levels; consider dose adjustment based on therapeutic drug monitoring. No specific dose adjustment established; use lowest effective dose.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
ALPHADERM (tretinoin 0.05% cream) is a retinoid used for photoaging and acne. Apply a pea-sized amount to dry skin 30 minutes after cleansing; avoid concomitant use of other topical retinoids or exfoliants to prevent irritation. Initiate therapy every other night to build tolerance. Strict sun protection required: use SPF 30+ daily. May cause initial flare of acne (retinoid 'purging') lasting 2-4 weeks. Contraindicated in pregnancy (FDA Category C).
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Apply a thin layer to affected areas once daily at bedtime, 30 minutes after washing and drying face.,Avoid excessive sun exposure; use broad-spectrum sunscreen and protective clothing.,Do not use with other medicated topical products, including benzoyl peroxide or salicylic acid.,Expect mild redness, peeling, or stinging initially; this usually subsides with continued use.,Notify your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Store at room temperature away from heat and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs ALPHADERM, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. ALPHADERM is a Topical Corticosteroid that works by Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and ALPHADERM depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of ALPHADERM is: Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and ALPHADERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . ALPHADERM is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.